ArisGen ^None

ArisGen is a drug delivery company that uses a proprietary technology to deliver therapeutic peptides orally or sub-lingually. They aim to transform the injectable peptide market by offering oral alternatives for medications. ArisGen is focused on developing its own products and partnerships to become a world leader in the development of orally available peptide drugs. They are currently developing a portfolio of novel products for the treatment of metabolic diseases and oncology, with a lead program being a fast-acting oral form of a GLP-1 agonist for diabetes treatment. ArisGen is committed to building an exceptional team and developing the next generation drug delivery system for peptide drugs.